drugset / Trial / NCT02769611
Ruboxistaurin in New York Heart Failure Classification III-IV Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study evaluates the effect of ruboxistaurin for its safety, tolerability, and effectiveness in treating adult patients with heart failure. Patients will receive 1 dose of oral ruboxistaurin.
Timeline
- Start
- 2017-06-28
- Primary completion
- 2022-01-01
- Completion
- 2022-01-01
Outcome
Outcome not reported
Stopped (Business): “No funding”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ruboxistaurin | Small molecule | 64 mg | Oral |
| Subject | Ruboxistaurin | Small molecule | 128 mg | Oral |
| Subject | Ruboxistaurin | Small molecule | 256 mg | Oral |